VENCLYXTO®▼ (venetoclax) in Acute Myeloid Leukaemia (AML)
In combination with a hypomethylating agent for newly-diagnosed patients with AML who are ineligible for intensive chemotherapy1
UK-VNCAML-220109 | April 2022
1. Venclyxto Summary of Product Characteristics
UK-VNCAML-220050. Date of Preparation: April 2022.
Resources
Downloadable materials for HCPs
Below are links to downloadable materials that may be useful to use as a reference in your routine clinical practice
Downloadable materials for your AML patients prescribed VENCLYXTO
Below are links to downloadable materials that may be useful to use as a reference in your routine clinical practice
Downloadable materials for the carers of your patients with AML
Below are links to downloadable materials that may be useful to use as a reference in your routine clinical practice
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
UK-VNCAML-220148. Date of preparation: June 2022.
